Browse > Article
http://dx.doi.org/10.15204/jkobgy.2018.31.3.152

A Case Study on Korean Medicine Treatment for the Oligomenorrhea with Increased Anti-mullerian Hormone Level  

Hong, Ka-Kyung (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University)
Kang, Su-Jin (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University)
Kim, Sun-Kyung (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University)
Kim, Song-Baek (Dept. of OB & GY, College of Oriental Medicine, Wonkwang University)
Publication Information
The Journal of Korean Obstetrics and Gynecology / v.31, no.3, 2018 , pp. 152-163 More about this Journal
Abstract
Objectives: In recent studies, increased AMH level has been suggested as objective surrogate marker for diagnosis PCOS, one of the major causes of oligomenorrhea. The purpose of this study is to report the clinical effect of Korean medicine treatment on oligomenorrhea patient with increased Anti-mullerian hormone level, who can be diagnosed who can be ruled out PCOS. Methods: A 27 year old woman with oligomenorrhea was enrolled in this study. We measured serum hormone levels and ruled out PCOS. The patient received Korean medicine treatment for 3 months, we assessed the result of treatment through observation of the menstrual cycle and follow-up measurements of serum hormone levels. Results: 1. The patient had menstrual cycle regularly. 2. Increased serum AMH level of the patient decreased from 12.16 ng/ml to 8.51 ng/ml. 3. The other serum hormone levels such as testosterone, LH/FSH ratio decreased Conclusion: This case shows that Korean medicine treatment could have a beneficial effect on menstrual cycle and decrease the increased serum hormone levels of ruled out PCOS patient.
Keywords
Oligomenorrhea; Anti-mullerian Hormone; PCOS (Polycystic Ovarian Syndrome); Korean Medicine Treatment;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Mun JB. Usefulness of Anti-mullerian Hormone for the Diagnosis of Polycystic Ovary Syndrome. Department of Medicine, Graduate school, Wonkwang university. 2014.
2 Seopgye(葉桂). Seopcheonsayeogwa(葉天士女科). Seoul:Daeseongmunhwasa. 1995:14-5.
3 Shin MK. Clinical Traditional Herbalogy. 2nd rev. ed. Seoul:Youngrimsa. 2010:213-558.
4 Oh TG, et al. Clinical Study for the One Case that Diagnosed Polycystic Ovarian Disease. The Journal Of Oriental Obstetrics & Gynecology. 2008;21(2):284-91.
5 Kim JR, et al. Clinical Study for the Four Cases of Secondary Amenorrhea and Hypomenorrhea by Hormone Assay. The Journal Of Oriental Obstetrics & Gynecology. 2009;22(3):267-76.
6 Korean Society of Obstetrics and Gynecology. Gynecology. 5th ed. Seoul: Korea Medical Book Publishing Company. 2015:81-493.
7 Kim JH, et al. A Study on the Characters of Oligomenorrheic Patients by Through Comparison of BMI, Yangorak, Menarche of Normal Menstrual Cycle Group and Oligomenorrheic Group. The Journal of Oriental Obstetrics & Gynecology. 2011;24(3):85-97.
8 Lee HY, Sung YH. Epidemiology and Diagnostic Criteria of Polycystic Ovary Syndrome. J Korean Diabetes. 2015;16(3):189-93.   DOI
9 You SY, et al. Anti-mullerian Hormone in Women with Polycystic Ovary Syndrome. Korean J obestet Gynecol. 2012;55(5):315-24.   DOI
10 Dumont A, et al. Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reproductive Biology and Endocrinology. 2015;13(1):137.   DOI
11 Song DK, et al. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Mullerian hormone cutoff value. Korean J Intern Med. 2017;32(4):690-8.   DOI
12 Dewailly D, et al. Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399-405.   DOI
13 Sung YH. Medical Diagnosis and Treatment of Polycystic Ovary Syndrome. The Korean Journal of Medicine. 2006;70(4):356-60.
14 Balen A, Conway G, Kaltsas G. Polycystic Ovary Syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107-11.   DOI
15 Sirmans SM, Pate KA. Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clinical Epidemiology. 2013;6(default):1-13.
16 The society of Korean medicine obstetrics and gynecology. Korean medicine obstetrics and gynecology. 3rd ed. Seoul:Uiseongdang. 2016:31-191.
17 Sung YA. Polycystic Ovary Syndrome in Korean Women: Clinical Characteristics and Diagnostic Criteria. Enadocrinol Metab. 2011;26(3):203-7.   DOI
18 Fauser B, et al. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome(PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steri. 2012;97(1):28-38.e25.   DOI
19 Yun SY, Kang MJ. Clinical Study of Oriental Medicine Treatment for Polycystic Ovarian Disease. The Journal Of Oriental Obstetrics & Gynecology. 2000;13(2):437-51.
20 Bili H. et al. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol. 2001;145(6):749-55.   DOI
21 Moran C, et al. Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):942-50.   DOI
22 Lee JR, Kim SH. Anti-Mullerian hormone and female reproduction. Korean J Obstet Gynecol. 2009;52(3):285-300.
23 La Marca A, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004;82(4):970-2.   DOI
24 Pigny P, et al. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941-5.   DOI
25 Li L, et al. Elevated serum antimullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17-18):519-24.   DOI
26 Woo HY, et al. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781-90.   DOI